Levin Capital Strategies L.P. increased its position in T2 Biosystems Inc (NASDAQ:TTOO) by 31.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 100,000 shares of the medical equipment provider’s stock after purchasing an additional 24,000 shares during the period. Levin Capital Strategies L.P.’s holdings in T2 Biosystems were worth $301,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently modified their holdings of the stock. Senvest Management LLC grew its stake in T2 Biosystems by 4.0% in the third quarter. Senvest Management LLC now owns 2,769,931 shares of the medical equipment provider’s stock worth $20,636,000 after purchasing an additional 105,800 shares during the period. BlackRock Inc. grew its stake in T2 Biosystems by 5.9% in the third quarter. BlackRock Inc. now owns 1,934,386 shares of the medical equipment provider’s stock worth $14,411,000 after purchasing an additional 108,575 shares during the period. Vanguard Group Inc grew its stake in T2 Biosystems by 8.6% in the third quarter. Vanguard Group Inc now owns 1,621,740 shares of the medical equipment provider’s stock worth $12,082,000 after purchasing an additional 128,724 shares during the period. Vanguard Group Inc. grew its stake in T2 Biosystems by 8.6% in the third quarter. Vanguard Group Inc. now owns 1,621,740 shares of the medical equipment provider’s stock worth $12,082,000 after purchasing an additional 128,724 shares during the period. Finally, Allianz Asset Management GmbH grew its stake in T2 Biosystems by 35.1% in the third quarter. Allianz Asset Management GmbH now owns 508,865 shares of the medical equipment provider’s stock worth $3,791,000 after purchasing an additional 132,227 shares during the period. 54.74% of the stock is currently owned by institutional investors.
In other news, CEO John Mcdonough sold 8,134 shares of the stock in a transaction on Monday, February 11th. The stock was sold at an average price of $3.36, for a total value of $27,330.24. Following the sale, the chief executive officer now directly owns 456,354 shares of the company’s stock, valued at $1,533,349.44. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last three months, insiders sold 34,587 shares of company stock worth $117,854. Insiders own 31.50% of the company’s stock.
NASDAQ TTOO opened at $3.45 on Wednesday. T2 Biosystems Inc has a 12 month low of $2.94 and a 12 month high of $9.98. The company has a debt-to-equity ratio of 1.66, a current ratio of 7.16 and a quick ratio of 6.81.
COPYRIGHT VIOLATION WARNING: “Levin Capital Strategies L.P. Purchases 24,000 Shares of T2 Biosystems Inc (TTOO)” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.com-unik.info/2019/02/13/levin-capital-strategies-l-p-purchases-24000-shares-of-t2-biosystems-inc-ttoo.html.
T2 Biosystems Profile
T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Featured Article: Why do earnings reports matter?
Want to see what other hedge funds are holding TTOO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for T2 Biosystems Inc (NASDAQ:TTOO).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.